Clinical trial will test monoclonal antibody in Parkinson’s disease
BioArctic says it has dosed the first patient with exidavnemab in the EXIST Phase IIa study in Parkinson’s disease patients. Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders… Read More